Related Experiment Video
Updated: Jun 3, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
[Secondary hyperparathyroidism--risk factor for development of cardiovascular complications in patients on
Dejan Petrović1, Biljana Stojimirović
1Klinicki centar Kragujevac, Kragujevac. aca96@eunet.rs
Insights
Secondary hyperparathyroidism significantly contributes to cardiovascular disease in hemodialysis patients. Early detection and management with non-calcium binders, vitamin D, and calcimimetics can reduce cardiovascular complications and mortality.
Area of Science:
- Nephrology
- Cardiology
- Endocrinology
Context:
- Cardiovascular disease (CVD) is a primary cause of mortality in patients undergoing hemodialysis.
- Secondary hyperparathyroidism (SHPT) is a major contributor to CVD in this population.
- Elevated parathormone, calcium, and phosphate levels, along with a high calcium-x-phosphate product, drive vascular and valvular calcification.
Purpose:
- To highlight the critical link between SHPT and cardiovascular complications in hemodialysis patients.
- To emphasize the importance of early screening for vascular/valvular calcification in hemodialysis patients.
- To advocate for timely intervention strategies to mitigate SHPT-related risks.
Summary:
- SHPT plays a pivotal role in the pathogenesis of cardiovascular complications, including coronary artery and valvular calcification, among hemodialysis patients.
- Identifying patients with vascular/valvular calcification is crucial for risk stratification and preventing the progression of coronary artery calcification.
- Management strategies include utilizing non-calcium-based phosphate binders, novel vitamin D analogs, and calcimimetics.
Impact:
- These interventions can effectively prevent or slow the development of SHPT and associated cardiovascular complications.
- Implementing these therapeutic approaches can significantly decrease cardiovascular morbidity and mortality rates in hemodialysis patients.
- Early detection and management of SHPT are essential for improving long-term outcomes in the hemodialysis population.
Abstract:
INTRODUCTION Cardiovascular disease is a leading cause of death among hemodialysis patients.
Secondary Hyperparathyroidism:
Secondary hyperparathyroidism is one of the main factors for the development of cardiovascular complications among these patients. A high concentration of parathormone, hypercalcemia, hyperphosphatemia and high calcium x phosphate product among dialysis patients play a crucial role in the development of vascular (calcification of coronary artery) and valvular calcifications. DISCUSSION AND CONCLUSION With every new patient on hemodialysis it is necessary to see if there is a vascular/valvular calcification in order to single out the patients at risk of progression of coronary artery calcification and to use non-calcium containing binder phosphate in due time. Non-calcium containing binder phosphate, new active vitamin D agents and calcimimetics prevent the development of secondary hyperparathyroidism as well as cardiovascular complications and decrease the rate of cardiovascular morbidity and mortality of these patients.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Hemodialysis II: Procedure and Complications
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease I: Introduction
Hemodialysis III: Nursing Management
